The FDA has granted priority review to Intellia’s biologics license application for lonvo-z and plans to issue a decision by March 10, 2027.
The accelerated approval was based on results from the Phase I/II SOHO-01 trial showing a 75 percent response rate to ...
NEW YORK - Partillion Bioscience announced Wednesday that it received a two-year, $2.1 million research award from the National Institutes of Health Small Business Innovation Research (SBIR) program, ...
The firm will study CT-202 in patients with nextin-4-positive colorectal, urothelial, and triple-negative breast cancers.
NEW YORK – Revvity said on Wednesday that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a French biotechnology company commercializing human cell models and ...
The investment bank gave Grail a price target of $105 and Caris, Tempus, and Twist price targets of $28, $70, and $144, respectively.
Editas Medicine said it has appointed Dan Ory as the firm's chief medical officer, effective Sept. 8.
NEW YORK – HeartBeat.bio and Cubase Bio announced Tuesday that they will collaborate in the pursuit of discovering new drugs for cardiovascular disease under a new EU-funded project.
The assay, which detects 19 variants in the DPYD gene, was first introduced in Europe as a research-use-only product in May.
The certificate, obtained under the EU's In Vitro Diagnostics Regulation, will allow the Cambridge, UK-based company to offer its test across the region.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results